RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliffJune 24, 2022 - The pharmaceutical and life sciences industry is poised for a “flurry of deals” in the second half, according to PwC.
In a new report covering the first half of the year, the professional services firm acknowledges there’s been a slow start to deal activity. But Big Pharmas are flush with cash—especially those that managed to tap into the COVID-19 market—biotech valuations are finally starting to normalize and many large companies face patent cliffs and are in need of new assets to bulk up their pipeline. All of this spells a second half that should be rich with deals.
Particularly of interest for Big Pharmas hunting for biotechs are early-stage companies and bolt-on transactions. The U.S. Federal Trade Commission has become increasingly particular about large-scale deals, which means transactions in the range of $5 billion to $15 billion might be more appetizing to those hunting. This also provides Big Pharma with the opportunity to “take multiple shots on goal” to make up for that soon-to-come generic competition. There still could be some blockbuster deals, though, PwC noted.
https://www.fiercebiotech.com/biotech/ma-down-big-pharma-likely-line-multiple-shots-goal-heading-2nd-half